These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32347114)

  • 61. Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan) in children.
    Bowman RJ; Cope J; Nischal KK
    Eye (Lond); 2004 Jan; 18(1):24-6. PubMed ID: 14707960
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Sensitization to and allergic contact dermatitis caused by Mirvaso(®) (brimonidine tartrate) for treatment of rosacea - 2 cases.
    Bangsgaard N; Fischer LA; Zachariae C
    Contact Dermatitis; 2016 Jun; 74(6):378-9. PubMed ID: 27133629
    [No Abstract]   [Full Text] [Related]  

  • 63. Clinical success and quality of life with brimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular t hypertension: a randomized clinical trial. Brimonidine Outcomes Study Group I.
    Javitt JC; Schiffman RM
    J Glaucoma; 2000 Jun; 9(3):224-34. PubMed ID: 10877373
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Ocular perfusion pressure and visual field indice modifications induced by alpha-agonist compound (clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2%) topical administration. An acute study on primary open-angle glaucoma patients.
    Costagliola C; Parmeggiani F; Ciancaglini M; D'Oronzo E; Mastropasqua L; Sebastiani A
    Ophthalmologica; 2003; 217(1):39-44. PubMed ID: 12566871
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Evaluation of Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution, 0.025% for Treatment of Ocular Redness.
    Torkildsen GL; Sanfilippo CM; DeCory HH; Gomes PJ
    Curr Eye Res; 2018 Jan; 43(1):43-51. PubMed ID: 29120262
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Brimonidine in the prevention of intraocular pressure elevation following argon laser trabeculoplasty.
    David R; Spaeth GL; Clevenger CE; Perell HF; Siegel LI; Henry JC; Stiles MC; Passo MS; Stamper RL; Walt JG
    Arch Ophthalmol; 1993 Oct; 111(10):1387-90. PubMed ID: 8105773
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effect of Ultra-Small Chitosan Nanoparticles Doped with Brimonidine on the Ultra-Structure of the Trabecular Meshwork of Glaucoma Patients.
    Barwal I; Kumar R; Dada T; Yadav SC
    Microsc Microanal; 2019 Dec; 25(6):1352-1366. PubMed ID: 31018876
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Selective α2-agonists in the treatment of glaucoma: pharmacology, efficacy and safety].
    Kurysheva NI
    Vestn Oftalmol; 2019; 135(2):144-150. PubMed ID: 31215546
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Brimonidine Toxicity Secondary to Topical Use for an Ulcerated Hemangioma.
    Gill K; Bayart C; Desai R; Golden A; Raimer P; Tamburro J
    Pediatr Dermatol; 2016 Jul; 33(4):e232-4. PubMed ID: 27282306
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering.
    Simmons ST; Earl ML;
    Ophthalmology; 2002 Feb; 109(2):307-14; discussion 314-5. PubMed ID: 11825814
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma. ALPHAGAN/XALATAN Study Group.
    Simmons ST; Samuelson TW
    Clin Ther; 2000 Apr; 22(4):388-99. PubMed ID: 10823361
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial.
    Sherwood MB; Craven ER; Chou C; DuBiner HB; Batoosingh AL; Schiffman RM; Whitcup SM
    Arch Ophthalmol; 2006 Sep; 124(9):1230-8. PubMed ID: 16966616
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Neuropsychiatric Adverse Events from Topical Ophthalmic Timolol.
    Cimolai N
    Clin Med Res; 2019 Dec; 17(3-4):90-96. PubMed ID: 31462538
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The chemotactic properties of various topical brimonidine tartrate ophthalmic preparations.
    Alonso RS; Solari HP; de França Damasceno E; Burnier MNN; Ventura MP
    BMC Pharmacol Toxicol; 2020 Mar; 21(1):24. PubMed ID: 32293549
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Brimonidine-induced unilateral ocular lichen planus: a case report.
    Ventura-Abreu N; Fernández-Aceñero MJ; Narváez-Palazón C; Romo-López A
    Arq Bras Oftalmol; 2019; 82(3):236-238. PubMed ID: 30916215
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Latanoprost and brimonidine: therapeutic and physiologic assessment before and after oral nonsteroidal anti-inflammatory therapy.
    Sponsel WE; Paris G; Trigo Y; Pena M; Weber A; Sanford K; McKinnon S
    Am J Ophthalmol; 2002 Jan; 133(1):11-8. PubMed ID: 11755835
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Brimonidine hypersensitivity when switching between 0.2% and 0.15% formulations.
    Sullivan-Mee M; Pensyl D; Alldredge B; Halverson K; Gerhardt G; Qualls C
    J Ocul Pharmacol Ther; 2010 Aug; 26(4):355-60. PubMed ID: 20653479
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Randomized trial of brinzolamide/brimonidine versus brinzolamide plus brimonidine for open-angle glaucoma or ocular hypertension.
    Gandolfi SA; Lim J; Sanseau AC; Parra Restrepo JC; Hamacher T
    Adv Ther; 2014 Dec; 31(12):1213-27. PubMed ID: 25430900
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Ocular comfort of combination glaucoma therapies: brimonidine 0.2%/timolol 0.5% compared with dorzolamide 2%/timolol 0.5%.
    Chan K; Testa M; McCluskey P
    J Ocul Pharmacol Ther; 2007 Aug; 23(4):372-6. PubMed ID: 17803436
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study.
    Layton AM; Schaller M; Homey B; Hofmann MA; Bewley AP; Lehmann P; Nohlgård C; Sarwer DB; Kerrouche N; Ma YM
    J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2405-10. PubMed ID: 26416154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.